When restricting to patients only in stages I and II (n = 163), there was a significant correlation with survival (HR = 0.4, p = 0.0015, median survival in the low-expression cohort = 18.3 months, median survival in the high-expression cohort = 75.6 months) (Figure 1C), suggesting DAPK1 expression is a prognostic marker in the early stages of ovarian cancer. Here, DAPK1 is linked to ovarian cancer.